NEW YORK (GenomeWeb) – Bionano Genomics and Genoptix today announced an exclusive agreement to codevelop diagnostic assays for selected hematologic oncology indications.

Bionano will contribute its knowledge of genome structure analysis and its Saphyr system, which is designed to accurately visualize the structure of a genome with a simple DNA sample, isolated directly from cancer cells. The platform can detect all major types of structural variants with greater sensitivity than sequence-based methods, according to Bionano.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.